Relationship between clinical efficacy of electroconvulsive therapy with Matrix Metalloproteinase-9 and Stromal cell-derived factor-1a serum levels in patients with mania

Relationship between clinical efficacy of electroconvulsive therapy with Matrix Metalloproteinase-9 and Stromal cell-derived factor-1a serum levels in patients with mania.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201410221556N66

Enrollment

Registered

2014-10-26

Start date

2014-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bipolar disorder type one-manic episode. bipolar affective disorder

Interventions

ECT method will be bitemporal. At the beginning 20 miliclombus will be administered and if the duration of seizure fail to reach 25 seconds, then the energy will be raised 25-50 percent. If seizure du

Treatment - Other

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) diagnosis by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013), of a bipolar I disorder (manic episode) 2) age between 18 to 45 years old 3) The minimal score on Young Mani Rating Scale (YMRS)=20 4) Signed informed consent 5) IQ>70 6) ASA class 1 or 2 Exclusion criteria: 1) a history of ECT during the preceding 6-month period; (2) use of nonbenzodiazepine anticonvulsants (valproate, carbamazepine, lamotrigine, or topiramate), lidocaine, theophylline, or lithium during the last week; (3) a history of rapid-cycling or mixed bipolar illness, schizophrenia, or another psychotic disorder that was not part of the mood disorder; (4) neurological illness or severe medical illness, 5) pregnancy, 6) stroke within the past 3 months, 7) brain surgery 8) severe head trauma, 9) drug or alcohol dependence within the past 2 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of mania. Timepoint: 24 hours before beginning ECT and 24 hours after first, third and sixth sessions of ECT. Method of measurement: by Young Mania Rating Scale (YMRS).;Serum level of MMP9. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.;Serum level of SDF1a. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.	—

Measure

Time frame

Severity of mania. Timepoint: 24 hours before beginning ECT and 24 hours after first, third and sixth sessions of ECT. Method of measurement: by Young Mania Rating Scale (YMRS).;Serum level of MMP9. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.;Serum level of SDF1a. Timepoint: before anesthesia, 10 minutes, and 6 hours after first, thisrd and sixth sessions of ECT. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzin Rezaei

Kurdistan University of Medical Sciences

farrezaei@muk.ac.ir frrezaie@yahoo.com+98 87 3366 0025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026